Results 251 to 260 of about 180,947 (337)

Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center

open access: diamond
Michael Colwill   +10 more
openalex   +1 more source

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study [PDF]

open access: bronze, 2011
David Laharie   +8 more
openalex   +1 more source

Patterns of parenteral nutrition use in the inpatient setting: A retrospective cohort study

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Parenteral nutrition (PN) supports patients unable to absorb sufficient nutrients from their gastrointestinal tracts. Yet, information about the patterns and extent of PN's in‐hospital use is lacking. Data on this topic should provide comparison points for nutrition support teams and hospital administrators examining PN use in their
Marc Romain   +7 more
wiley   +1 more source

Adolescent Crohn's disease: A nursing case report. [PDF]

open access: yesMedicine (Baltimore)
Wang X, Zhang N, Ma H.
europepmc   +1 more source

Self-reported sleep disturbance in Crohn’s disease is not confrmed by objective sleep measures [PDF]

open access: yes, 2020
Ciorba, Matthew A.   +7 more
core   +1 more source

Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto   +2 more
wiley   +1 more source

Can Creeping Fat Be a Prognostic Factor in Crohn's Disease? [PDF]

open access: yesTurk J Gastroenterol
Demiral N   +6 more
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy